Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11.

摘要: Introduction:  The addition of a long-acting β2 agonist (LABA) to inhaled corticosteroid (ICS) may control asthma better than ICS alone. Eosinophil markers predict symptom severity in asthma. Objectives:  effect combination treatment on moderate severe asthmatics not selected respond rapidly steroid deprivation was compared with monotherapy. ability serum assessed. Methods:  Asthmatics treated adequately (750–1000 mcg daily) were randomised receive (fluticasone propionate) + LABA (salmeterol) (500 mcg/50 mcg bd) or alone (500 mcg bd). If controlled at clinic visits every 6 weeks, dose tapered until exacerbated (hospitalisation, above study medication, peak flow variation, decline forced expiratory volume 1 s and/or use rescue medication), placebo maintained for weeks. Efficacy the treatments compared. Serum cytokines and chemokines among groups reporting severe, mild no symptoms. Results:  There difference between arms clinical analysis. Nine patients could be 36 developed symptoms 16 symptoms. Patients weeks had significantly lower eotaxin baseline intermediate concentrations. Conclusion:  heterogeneously tapering. eotaxin/CCL11 useful predicting develop during tapering should evaluated guiding treatment. Please cite this paper as: Hoffmann HJ, Nielsen LP, Harving H, Heinig JH Dahl R. able step down from without loss have low eotaxin/CCL11. Clinical Respiratory Journal 2008; 2: 149–157.